Spelling suggestions: "subject:"arginine metabolism"" "subject:"larginine metabolism""
1 |
Anti-tumor effects and mechanisms of pegylated human recombinant arginase (PEG-BCT-100) in pancreatic cancer cells: 一種聚乙二醇重組人精氨酸酶在胰腺癌細胞中的抗癌效應及機制研究 / 一種聚乙二醇重組人精氨酸酶在胰腺癌細胞中的抗癌效應及機制研究 / CUHK electronic theses & dissertations collection / Anti-tumor effects and mechanisms of pegylated human recombinant arginase (PEG-BCT-100) in pancreatic cancer cells: Yi zhong ju yi er chun zhong zu ren jing an suan mei zai yi xian ai xi bao zhong de kang ai xiao ying ji ji zhi yan jiu / Yi zhong ju yi er chun zhong zu ren jing an suan mei zai yi xian ai xi bao zhong de kang ai xiao ying ji ji zhi yan jiuJanuary 2015 (has links)
Pancreatic cancer is one of the most devastating human cancers with the lowest survival rate among 24 commonly diagnosed cancers. It is the seventh and the sixth leading cause of cancer-related deaths in the world and Hong Kong respectively. The current pancreatic cancer treatment options, have limited efficacy and undesirable side effects. Because of the high mortality rate and unsatisfactory treatment outcome, it is necessary to develop new strategies for pancreatic cancer therapy. / In human, an abundant arginine reserve is known to be crucial for tumor cell proliferation. Arginine is a semi-essential amino acid because most of the somatic cells can re-synthesize it from other metabolites like citrulline in urea cycle. However, arginine auxotrophy is observed in certain tumors, such as hepatocarcinoma, melanoma and sarcoma, where restriction or depletion of arginine will lead to tumor death. Further studies have found that deficiency in either argininosuccinate synthetase 1 (ASS1) or ornithine transcarbamylase (OTC) expression contributes to arginine auxotrophy in these tumors. These findings implicated the potential of using arginine deprivation as a novel pancreatic cancer treatment strategy. / PEG-BCT-100 is a pegylated recombinant human arginase that metabolizes arginine into urea and ornithine. This study examined the preclinical anti-tumor efficacy of PEG-BCT-100 and the underlying mechanism in pancreatic cancer. Six pancreatic cancer cell lines AsPC-1, BxPC-3, CFPAC-1, Capan-2, MIA PaCa-2 and Panc10.05 were used as in vitro cell model. Cell growth was either completely stopped or dramatically reduced in arginine-free medium, suggesting pancreatic cancer cells were arginine auxotrophic. The protein and mRNA expression levels of the ASS1, OTC and argininosuccinate lyase (ASL), which are enzymes involved in arginine, were studied. The results showed that ASL was highly expressed in all cell lines, suggesting it is not an essential regulator in arginine auxotrophy in pancreatic cancer. On the other hand, ASS1 was only detected in BxPC-3 and CFPAC-1, while OTC was undetectable in all cell lines in both mRNA and protein levels. The effect of PEG-BCT-100 was illustrated via cell cycle progression, cell proliferation and viability. Single drug effect combining PEG-BCT-100 with other anti-tumor drugs, such as 5-FU and gemcitabine, was further explored. Synergistic effect of PEG-BCT-100 and gemcitabine under combination of PEG-BCT-100 and gemcitabine was observed in CFPAC-1 and MIA PaCa-2. Overexpression of OTC and ASS1 decreased the sensitivity of towards PEG-BCT-100 significantly. Taken together, OTC deficiency is a potential indicative marker for the sensitivity of arginine depletion treatment in pancreatic cancer. / 胰腺癌是最具毀滅性的人類癌症之一,在二十四種常見的癌症中,它有着最低的存活率。儘管不在發病率最高的十種癌症中,胰腺癌仍舊是世界第七大致死癌症,以及香港第六大致死癌症。手術治療,放射治療,以及化學藥物治療是現今常用的胰腺癌治療手段,但是這些療法不是限制繁多,就是收效甚微,並常常伴有強烈的副作用。由於胰腺癌具有很高的致死率以及缺乏有效的治療方法,所以新的治療策略亟待開發。 / 於人類而言,精氨酸是一種半必需氨基酸,因爲它可以通過尿素循環中的其他代謝產物,如鳥氨酸以及瓜氨酸,重新合成。然而,精氨酸缺陷出現在多種腫瘤中,像肝癌,黑色素瘤,以及血癌。限制或者減少精氨酸的供應會導致這些腫瘤死亡。除此之外,腫瘤細胞的快速生長也依賴於充足的精氨酸。進一步的研究表明,在這些腫瘤中,精氨琥珀酸合成酶1(ASS1)或者鳥氨酸氨甲醯基轉移酶(OTC)的任意一個缺乏都會導致精氨酸缺陷。本文將探討將剝奪精氨酸作爲一種新策略來治療胰腺癌的可行性。 / PEG-BCT-100又名金氨素,是一種聚乙二醇化重組人精氨酸酶,它可以催化精氨酸分解爲尿素和鳥氨酸。我們研究了PEG-BCT-100在胰腺癌細胞中的抗癌效果以及探討了與其相關的作用機理。在我們的研究中,AsPC-1, BxPC-3, CFPAC-1, Capan-2, MIA PaCa-2以及Panc10.05這六個細胞株用作體外的細胞模型。爲了評估PEG-BCT-100治療胰腺癌的可行性,我們首先調查了精氨酸對胰腺癌細胞的重要性。通過將這些胰腺癌細胞培養在有精氨酸供應和沒有精氨酸供應的完全培養基中,我們發現剝奪精氨酸能完全停止或者極大地減少了胰腺癌細胞的生長。這說明了這些胰腺癌細胞也都是精氨酸營養缺陷型的細胞。通過蛋白印跡和實時定量聚合酶鏈式反應實驗,我們進一步研究了精氨酸代謝相關基因在這些胰腺癌細胞中的表達水平。結果表明,精氨琥珀酸裂解酶(ASL)在全部的六條細胞系中都有被檢測到。ASS1只出現在BxPC-3和CFPAC-1中。然而在全部的細胞中,無論是蛋白質水平還是mRNA水平,OTC都沒有被檢測到。緊接着,我們研究了PEG-BCT-100在胰腺癌細胞活力,細胞增殖,細胞週期以及細胞凋亡等方面的影響。結果表明,PEG-BCT-100可以從多個方面抑制胰腺癌細胞。我們還嘗試探索了PEG-BCT-100與其他胰腺癌治療藥物在胰腺癌細胞中的聯合使用效果。然後發現PEG-BCT-100與吉西他滨(gemcitabine)聯合使用具有協同效果。最後,我們構建了四種不同表達類型的MIA PaCa-2細胞模型:(ASS1-/OTC-), (ASS1-/OTC+), (ASS1+/OTC-)以及(ASS1+/OTC+)。接着我們測試了PEG-BCT-100在這些細胞模型中的效果。結果表明,同時在MIA PaCa-2細胞中表達ASS1和OTC可以明顯地提高其對PEG-BCT-100的抗性,單表達其中一個基因對PEG-BCT-100的抗性也有些許提高,但效果不如雙表達明顯。 / 總而言之,對於胰腺癌細胞而言,精氨酸是必不可少的。PEG-BCT-100有很明顯的胰腺癌效果。在胰腺癌中,OTC的表達情況可以作爲預估PEG-BCT-100治療效果的重要生物標誌。 / Deng, Haohao. / Thesis M.Phil. Chinese University of Hong Kong 2015. / Includes bibliographical references (leaves 111-117). / Abstracts also in Chinese. / Title from PDF title page (viewed on 14, October, 2016). / Deng, Haohao. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only.
|
2 |
An investigation of endogenous ghrelin and growth hormone-releasing hormone following the consumption of two different relative doses of oral l-arginineMcCarthy, Amanda Marie Unknown Date
No description available.
|
3 |
The effects of oral supplementation of the amino acid arginine on body composition and muscle function during energy restriction in male weight liftersHawkins, Colleen E. 14 March 2009 (has links)
Manufacturers of amino acid supplements claim that they can act as natural stercoids. Eighteen experienced male weight lifters were studied to test this hypothesis for the amino acid arginine. / Master of Science
|
4 |
Biochemical determinants of nitric oxide synthesis in severe malariaAlkaitis, Matthew S. January 2014 (has links)
Inhibition of nitric oxide (NO) signalling may contribute to the pathogenesis of severe malaria. This thesis examines the impact of Plasmodium infection on three key determinants of nitric oxide synthase (NOS) biochemistry: substrate availability, substrate/inhibitor homeostasis and cofactor availability. Arginine, the NOS substrate, is depleted in human patients with severe Plasmodium falciparum malaria and mice infected with P. berghei ANKA. Using heavy isotope tracer infusions to quantify arginine metabolism in infected mice, we found no evidence of increased catabolism by the enzyme arginase, widely assumed to be responsible for arginine depletion. Genetic knock-out of parasite arginase had no effect on arginine depletion in mice. Instead, our findings link arginine depletion to decreased rates of arginine and citrulline appearance in the plasma of infected mice. Asymmetric dimethylarginine (ADMA) competes with arginine for binding to the NOS catalytic site. We observed elevation of the ADMA/arginine ratio in Gambian children with severe malaria, favouring NOS inhibition. In mice infected with P. berghei ANKA, we found evidence of degradation of dimethylarginine dimethylaminohydrolase 1 (DDAH1), the enzyme primarily responsible for ADMA metabolism. We also observed reduced DDAH activity and accumulation of intracellular ADMA in hepatic tissue of infected mice, suggesting that DDAH dysfunction could contribute to disruption of ADMA/arginine homeostasis. Tetrahydrobiopterin (BH4) is an essential NOS cofactor. In P. berghei ANKA-infected mice, BH4 concentrations were decreased in plasma, erythrocytes and brain tissue, which could inhibit NO synthesis and promote NOS-dependent superoxide production. To reverse deficiencies of NOS substrate and cofactor availability, we infused P. berghei ANKA-infected mice with citrulline, an arginine precursor, and sepiapterin, a BH4 precursor. Restoration of systemic arginine and BH4 availability in infected mice improved whole blood nitrite concentrations, a biomarker of NO synthesis, but did not prevent onset of disease symptoms. These studies have identified biochemical disturbances that may contribute to severe malaria pathogenesis by inhibiting NO synthesis.
|
5 |
Supplémentation nutritionnelle en arginine chez des sujets sains présentant des facteurs de risque liés au syndrome métabolique : métabolisme de l'arginine alimentaire et impact sur la fonction endothéliale / Nutritional arginine supplementation in healthy subjects with risk factors associated with metabolic syndrome : dietary arginine metabolism and impact on endothelial functionDeveaux, Ambre 01 April 2016 (has links)
La dysfonction endothéliale vasculaire, processus majeur initiant l’athérosclérose, est étroitement liée à l’altération de la synthèse et/ou biodisponibilité du monoxyde d’azote (NO), dont l’arginine est le précurseur. Elle apparait aussi dès la phase postprandiale après un repas gras et sucré. Chez des sujets avec des facteurs de risque cardiométabolique, une supplémentation orale en arginine a un effet bénéfique sur des fonctions associées au NO. Aucune donnée ne permet cependant de lier la mise à disposition de l’arginine et la synthèse de NO, en situation normale ou de risque cardiométabolique. De plus, peu d’études ont étudié l’effet d’une supplémentation en arginine, dans un contexte nutritionnel (faible dose et libération lente) chez des sujets avec des facteurs de risque cardiométabolique. Ce travail vise donc à évaluer l’effet d’une supplémentation nutritionnelle en arginine, sur le métabolisme de l’arginine et la fonction endothéliale (FE), chez des sujets sains présentant des facteurs de risque cardiométabolique. Dans une première étude clinique, nous avons ainsi comparé la biodisponibilité de l’arginine ingérée et son utilisation pour la synthèse de NO, selon la présence de facteurs de risque cardiométabolique, et selon qu’elle était consommée sous une forme à libération immédiate (LI) ou sous une forme à libération prolongée (LP), mimant la mise à disposition naturelle de l’arginine alimentaire. Puis, dans une deuxième étude clinique, nous avons étudié l’effet de la supplémentation en arginine LP sur la FE à jeun et sur son altération postprandiale, chez des sujets sains présentant des facteurs de risque cardiométabolique; et si cet effet pourrait varier selon leur argininémie basale. Ce travail de thèse a ainsi mis en évidence une utilisation de l’arginine ingérée plus élevée pour la synthèse de NO chez les sujets avec des facteurs de risque cardiométabolique, et plus élevée avec la forme LP qu’avec la forme LI, en particulier chez ces sujets à risque. La deuxième étude, quant à elle, a révélé que les effets de la supplémentation en arginine-LP variaient selon l’argininémie basale des sujets présentant des facteurs de risque cardiométabolique. Chez les sujets avec une argininémie basale relativement plus faible, l’arginine-LP a atténué la diminution postprandiale de la FE et a conduit à une FE significativement meilleure à la fin de la période postprandiale. / Vascular endothelial dysfunction, the hallmark of early atherosclerosis, results from an impairment of the synthesis and/or bioavailability of nitric oxide (NO), the precursor of which is arginine. Endothelial dysfunction is also known to be induced transiently by a high-fat meal. In subject with cardiometabolic risk factors, oral arginine supplementation has a beneficial effect on NO-related physiological functions. However, no data relates the availability of arginine to the synthesis of NO in normal or cardiometabolic risk condition. In addition, few studies only have investigated the effect of arginine supplementation in a nutritional context (low dose and slow release) in subjects with cardiometabolic risk factors. This work aims to evaluate the effect of a nutritional arginine supplementation, on the arginine metabolism and endothelial function in healthy subjects with cardiometabolic risk factors. In a first clinical study, we have compared the bioavailability of oral arginine and its utilization for NO synthesis, as a function of the presence of cardiometabolic risk factors, and as a function of the form of release (immediate release, IR, as free arginine, or sustained release, SR, which mimics the slow release of dietary arginine). Then, in a second clinical study, we studied the effect of SR-arginine supplementation on fasting endothelial function and its postprandial alteration in healthy subjects with cardiometabolic factors. A further aim was to investigate whether this effect may vary according to the baseline arginine status of subjects. This thesis work has demonstrated a higher utilization of oral arginine for NO synthesis in subjects with cardiometabolic risk factors, and a higher utilization with the SR form, particularly in these subjects at risk. As to the second study, it showed that the SRarginine supplementation effects largely varied with baseline fasting arginine concentration of subjects with cardiometabolic risk factors. In subjects with a relatively lower baseline arginine concentration, SR-arginine attenuated the decrease in postprandial endothelial function and led to a significantly higher endothelial function at the end of the postprandial period.
|
Page generated in 0.0807 seconds